European Union - English - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

United States - English - NLM (National Library of Medicine)

amgen inc - ivabradine hydrochloride (unii: tp19837bzk) (ivabradine - unii:3h48l0lpzq) - ivabradine 5 mg - corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.  corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (dcm) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. corlanor is contraindicated in patients with: • acute decompensated heart failure • clinically significant hypotension • sick sinus syndrome, sinoatrial block or 3rd degree av block, unless a functioning demand pacemaker is present • clinically significant bradycardia [see warnings and precautions ( 5.3 )] • severe hepatic impairment [see use in specific populations ( 8.6 )] • pacemaker dependence (heart rate maintained exclu